Annual report
8086.TEDINET S100W5PM
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥644.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥586.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥455.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥26.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥22.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥19.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.2bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥6.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥12.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.03T | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥930.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥854.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥858.9bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥840.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥311.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥269.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥242.2bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥174.1bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥106.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥99.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥101.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥68.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥72.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥66.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥71.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥87.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.7bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥45.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥22.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥43.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥22.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥31.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.12 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.12 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥60.35 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,547.82 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,426.56 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,265 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥987.3 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 21.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 39,168 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 38,117 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 38,770 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 36,259 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 35,251 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥393.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥368.3bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥349.7bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥334.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥8.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥5.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥9.7bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.3bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥10.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥18.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥6.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥8.7bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥825.7bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥808.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥764.9bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥727.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥695.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥629.9bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥621.1bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥195.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥187.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥181.6bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥179.7bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥173.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥22.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥23.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥115.54 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.1 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.47 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.72 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥102.37 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥37.3 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥47.38 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥25 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,200.51 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,149.68 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,113.64 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,065.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 23.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,563 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 4,388 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4,390 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 4,252 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,150 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥525m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 146 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥250.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥245m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥7.5bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥83.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥83.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥171.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥30.6bn |
| Medical Treatment Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥41.5bn |
| Medical Treatment Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥34.8bn |
| Medical Treatment Relatedreportable segment | employees | at 2025-03-31 | 27649 pure |
| Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥512.0bn |
| Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥505.1bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2025-03-31 | ¥711.9bn |
| Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥46.6bn |
| Medicine Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥19.8bn |
| Medicine Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥15.3bn |
| Medicine Relatedreportable segment | employees | at 2025-03-31 | 7982 pure |
| Medicine Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥143.0bn |
| Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥79.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥63.8bn |
| Medicine Relatedreportable segment | segment assets | at 2025-03-31 | ¥266.4bn |
| Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥10.6bn |
| Pharma Packagingreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.7bn |
| Pharma Packagingreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Pharma Packagingreportable segment | employees | at 2025-03-31 | 2530 pure |
| Pharma Packagingreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥66.1bn |
| Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥59.3bn |
| Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6.8bn |
| Pharma Packagingreportable segment | segment assets | at 2025-03-31 | ¥113.4bn |
| Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥272m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥73.0bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥721.1bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥643.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥77.6bn |
| —segment total | segment assets | at 2025-03-31 | ¥1.09T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥57.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥74.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥728.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥644.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥83.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.34T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥57.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥739m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥407m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥5.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥816m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥4.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥234.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥80m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥71.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥71.4bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥142.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥27.0bn |
| Medical Treatment Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥48.7bn |
| Medical Treatment Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥29.1bn |
| Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥459.3bn |
| Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥453.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.7bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2024-03-31 | ¥663.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥42.3bn |
| Medicine Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥31.9bn |
| Medicine Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥15.0bn |
| Medicine Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥129.6bn |
| Medicine Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥74.3bn |
| Medicine Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥55.3bn |
| Medicine Relatedreportable segment | segment assets | at 2024-03-31 | ¥243.2bn |
| Medicine Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Pharma Packagingreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥14.5bn |
| Pharma Packagingreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.4bn |
| Pharma Packagingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥64.3bn |
| Pharma Packagingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥58.0bn |
| Pharma Packagingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Pharma Packagingreportable segment | segment assets | at 2024-03-31 | ¥110.7bn |
| Pharma Packagingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.5bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥95.1bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥50.5bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥653.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥586.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥67.2bn |
| —segment total | segment assets | at 2024-03-31 | ¥1.02T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥49.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥95.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥50.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥658.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥586.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥71.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.25T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥49.3bn |
| Medical Treatment Relatedreportable segment | employees | at 2025-03-31 | 3503 pure |
| Medicine Relatedreportable segment | employees | at 2025-03-31 | 28 pure |
| Pharma Packagingreportable segment | employees | at 2025-03-31 | 171 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,208
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes payable facilities | CurrentYearInstant | 4799000000 | JPY |
| Other cl | Prior1YearInstant | 45451000000 | JPY |
| Other cl | CurrentYearInstant | 51119000000 | JPY |
| Current liabilities | Prior1YearInstant | 366475000000 | JPY |
| Current liabilities | CurrentYearInstant | 350545000000 | JPY |
| Bonds payable | Prior1YearInstant | 82000000000 | JPY |
| Bonds payable | CurrentYearInstant | 103000000000 | JPY |
| Convertible bond type bonds with subscription rights to shares | Prior1YearInstant | 30150000000 | JPY |
| Convertible bond type bonds with subscription rights to shares | CurrentYearInstant | 30090000000 | JPY |
| Long term loans payable | Prior1YearInstant | 302819000000 | JPY |
| Long term loans payable | CurrentYearInstant | 309987000000 | JPY |
| Lease obligations ncl | Prior1YearInstant | 25312000000 | JPY |
| Lease obligations ncl | CurrentYearInstant | 25170000000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 1619000000 | JPY |
| Deferred tax liabilities | CurrentYearInstant | 2018000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 5675000000 | JPY |
| Net defined benefit liability | CurrentYearInstant | 7244000000 | JPY |
| Provision for directors retirement benefits | Prior1YearInstant | 557000000 | JPY |
| Provision for directors retirement benefits | CurrentYearInstant | 584000000 | JPY |
| Provision for loss on litigation ncl | Prior1YearInstant | 227000000 | JPY |
| Provision for loss on litigation ncl | CurrentYearInstant | 276000000 | JPY |
| Other ncl | Prior1YearInstant | 25195000000 | JPY |
| Other ncl | CurrentYearInstant | 30024000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 473557000000 | JPY |
| Noncurrent liabilities | CurrentYearInstant | 508397000000 | JPY |
| Liabilities | Prior1YearInstant | 840032000000 | JPY |
| Liabilities | CurrentYearInstant | 858942000000 | JPY |
| Capital stock | Prior1YearInstant | 84397000000 | JPY |
| Capital stock | CurrentYearInstant | 84397000000 | JPY |
| Capital surplus | Prior1YearInstant | 0 | JPY |
| Capital surplus | CurrentYearInstant | － | JPY |
| Retained earnings | Prior1YearInstant | 104321000000 | JPY |
| Retained earnings | CurrentYearInstant | 104783000000 | JPY |
| Treasury stock | Prior1YearInstant | -10749000000 | JPY |
| Treasury stock | CurrentYearInstant | -10749000000 | JPY |
| Shareholders equity | Prior1YearInstant | 177970000000 | JPY |
| Shareholders equity | CurrentYearInstant | 178431000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 9704000000 | JPY |
| Valuation difference on available for sale securities | CurrentYearInstant | 2741000000 | JPY |
| Deferred gains or losses on hedges | Prior1YearInstant | -50000000 | JPY |
| Deferred gains or losses on hedges | CurrentYearInstant | 176000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 43516000000 | JPY |
| Foreign currency translation adjustment | CurrentYearInstant | 68920000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 1524000000 | JPY |
| Remeasurements of defined benefit plans | CurrentYearInstant | 2172000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 54695000000 | JPY |
| Valuation and translation adjustments | CurrentYearInstant | 74010000000 | JPY |
| Subscription rights to shares | Prior1YearInstant | － | JPY |
| Subscription rights to shares | CurrentYearInstant | 4000000 | JPY |
| Non controlling interests | Prior1YearInstant | 37123000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |